BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20043095)

  • 1. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N; Tsukuda M; Kimura M; Fujita K; Sakakibara A; Takahashi H; Ishiguro Y; Toth G; Matsuda H
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A; Tsukuda M; Kondo N; Ishiguro Y; Kimura M; Fujita K; Takahashi H; Matsuda H
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase-specific virotheranostics for human head and neck cancer.
    Kurihara Y; Watanabe Y; Onimatsu H; Kojima T; Shirota T; Hatori M; Liu D; Kyo S; Mizuguchi H; Urata Y; Shintani S; Fujiwara T
    Clin Cancer Res; 2009 Apr; 15(7):2335-43. PubMed ID: 19318473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma.
    Fujita K; Kimura M; Kondo N; Sakakibara A; Sano D; Ishiguro Y; Tsukuda M
    Oncol Rep; 2008 Dec; 20(6):1363-8. PubMed ID: 19020715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M; Kagawa S; Nishizaki M; Mizuguchi H; Hayakawa T; Kyo S; Nagai K; Urata Y; Tanaka N; Fujiwara T
    Oncogene; 2005 Apr; 24(19):3130-40. PubMed ID: 15735729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conditionally replicating adenovirus improves gene replication efficiency and anticancer effect of E1-deleted adenovirus carrying TRAIL in head and neck squamous cell carcinoma.
    Shim SH; Lee CT; Hun Hah J; Lee JJ; Park SW; Heo DS; Sung MW
    Cancer Sci; 2010 Feb; 101(2):482-7. PubMed ID: 19922505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
    Toivonen R; Suominen E; Grenman R; Savontaus M
    Oncol Rep; 2009 Jan; 21(1):165-71. PubMed ID: 19082458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
    Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
    Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
    Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
    Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma.
    Adhim Z; Lin X; Huang W; Morishita N; Nakamura T; Yasui H; Otsuki N; Shigemura K; Fujisawa M; Nibu K; Shirakawa T
    Cancer Gene Ther; 2012 Feb; 19(2):144-52. PubMed ID: 22116375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
    Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y; Shen K; Yu JR
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Ge Y; VanRoey M; Robinson M; Jooss K
    Cancer Gene Ther; 2009 May; 16(5):383-92. PubMed ID: 19011598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymer chemotherapy for head and neck cancer.
    Shikani AH; Domb AJ
    Laryngoscope; 2000 Jun; 110(6):907-17. PubMed ID: 10852503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
    Dias JD; Liikanen I; Guse K; Foloppe J; Sloniecka M; Diaconu I; Rantanen V; Eriksson M; Hakkarainen T; Lusky M; Erbs P; Escutenaire S; Kanerva A; Pesonen S; Cerullo V; Hemminki A
    Clin Cancer Res; 2010 May; 16(9):2540-9. PubMed ID: 20388844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
    Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.